Breast Cancer

Evidence-based overview of Boswellia in breast cancer, including Phase Ia human data, EGFR signalling, and apoptosis research

Boswellia has one of its most important early human cancer datasets in breast cancer, which makes this a key page in the whole topic.

Overview

The breast cancer evidence includes a 2024 Phase Ia human trial plus substantial preclinical work on AKBA, EGFR, apoptosis, and metastasis-related biology.

Key human data

A 2024 window-of-opportunity Phase Ia trial reported a statistically significant reduction in tumour proliferation marker Ki67 with oral Boswellia serrata
Safety and tolerability were good in this early clinical setting
This is one of the stronger direct human-tissue signals for any Boswellia oncology use

Key preclinical data

AKBA showed strong cytotoxic, apoptotic, and anti-metastatic activity in breast cancer cell lines
EGFR phosphorylation and downstream PI3K/Akt signalling were inhibited in relevant models
Comparative work suggests AKBA and ABA may offer complementary biology in breast cancer settings

Clinical positioning

Breast cancer is one of the more important Boswellia pages because it combines real human data with strong mechanistic support.

References

The anti-proliferative effects of a frankincense extract in a window of opportunity Phase Ia clinical trial for patients with breast cancer
https://pmc.ncbi.nlm.nih.gov/articles/PMC10959833/

Comparative study of cytotoxicity, apoptotic, and epigenetic effects of boswellic acid derivatives on breast cancer
https://www.nature.com/articles/s41598-022-24229-y

Jump to another Boswellia page

Core pages

Mechanism deep dives

Practical pages

Cancer-type pages

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.